Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Abcellera Biologics Inc

ABCL
Current price
3.02 USD -0.04 USD (-1.31%)
Last closed 3.06 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 888 043 136 USD
Yield for 12 month -59.79 %
1Y
3Y
5Y
10Y
15Y
ABCL
21.11.2021 - 28.11.2021

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.25 USD

P/E ratio

Dividend Yield

Current Year

+38 025 000 USD

Last Year

+485 424 000 USD

Current Quarter

+9 954 000 USD

Last Quarter

+9 179 000 USD

Current Year

+7 131 000 USD

Last Year

+418 988 000 USD

Current Quarter

+3 188 000 USD

Last Quarter

+70 000 USD

Key Figures ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -203 502 000 USD
Operating Margin TTM -551.48 %
PE Ratio
Return On Assets TTM -9.59 %
PEG Ratio
Return On Equity TTM -12.56 %
Wall Street Target Price 15.25 USD
Revenue TTM 35 787 000 USD
Book Value 3.85 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -18.4 %
Dividend Yield
Gross Profit TTM 311 109 000 USD
Earnings per share -0.51 USD
Diluted Eps TTM -0.51 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 45.9 %
Profit Margin

Dividend Analytics ABCL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 27.4725
Enterprise Value Revenue 15.4496
Price Sales TTM 33.4168
Enterprise Value EBITDA -3.0572
Price Book MRQ 1.1027

Financials ABCL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABCL

For 52 weeks

2.99 USD 8.05 USD
50 Day MA 3.84 USD
Shares Short Prior Month 19 748 393
200 Day MA 4.62 USD
Short Ratio 14.25
Shares Short 18 417 566
Short Percent 8.73 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics